Is intracranial volume a risk factor for IDH-mutant low-grade glioma? A case-control study.
Brain neoplasms
HUNT study
Low-grade glioma
Magnetic resonance imaging
Risk factors
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
03
07
2022
accepted:
17
08
2022
pubmed:
28
8
2022
medline:
3
11
2022
entrez:
27
8
2022
Statut:
ppublish
Résumé
Risk of cancer has been associated with body or organ size in several studies. We sought to investigate the relationship between intracranial volume (ICV) (as a proxy for lifetime maximum brain size) and risk of IDH-mutant low-grade glioma. In a multicenter case-control study based on population-based data, we included 154 patients with IDH-mutant WHO grade 2 glioma and 995 healthy controls. ICV in both groups was calculated from 3D MRI brain scans using an automated reverse brain mask method, and then compared using a binomial logistic regression model. We found a non-linear association between ICV and risk of glioma with increasing risk above and below a threshold of 1394 ml (p < 0.001). After adjusting for ICV, sex was not a risk factor for glioma. Intracranial volume may be a risk factor for IDH-mutant low-grade glioma, but the relationship seems to be non-linear with increased risk both above and below a threshold in intracranial volume.
Identifiants
pubmed: 36029398
doi: 10.1007/s11060-022-04120-6
pii: 10.1007/s11060-022-04120-6
pmc: PMC9622551
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-106Informations de copyright
© 2022. The Author(s).
Références
Radiology. 2000 Sep;216(3):672-82
pubmed: 10966694
AJNR Am J Neuroradiol. 2015 Aug;36(8):1450-6
pubmed: 25857759
Proc Biol Sci. 2020 Dec 23;287(1941):20202291
pubmed: 33323077
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Epidemiol Rev. 2001;23(2):313-42
pubmed: 12192740
Neuro Oncol. 2019 Mar 18;21(4):451-461
pubmed: 30624711
Neuro Oncol. 2017 Jul 01;19(7):976-985
pubmed: 28040713
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20482-20488
pubmed: 31548407
Nat Neurosci. 2016 Dec;19(12):1569-1582
pubmed: 27694991
Neuro Oncol. 2018 Aug 2;20(9):1225-1230
pubmed: 29554311
Science. 2015 Jan 2;347(6217):78-81
pubmed: 25554788
Int J Epidemiol. 2013 Aug;42(4):968-77
pubmed: 22879362
Neurooncol Adv. 2021 Jul 08;3(1):vdab098
pubmed: 34738083
Neurobiol Aging. 2008 Nov;29(11):1754-62
pubmed: 17544173
Front Neurosci. 2015 Jul 09;9:238
pubmed: 26217172
Neurooncol Pract. 2022 Feb 22;9(3):165-182
pubmed: 35601966
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Comp Neurol. 2016 Dec 15;524(18):3865-3895
pubmed: 27187682
Neuro Oncol. 2022 Feb 1;24(2):302-310
pubmed: 34387331
PLoS One. 2016 Mar 07;11(3):e0151080
pubmed: 26950220
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Nat Genet. 2017 May;49(5):789-794
pubmed: 28346443
Behav Genet. 2000 Jul;30(4):311-9
pubmed: 11206086
Neuro Oncol. 2021 Aug 2;23(8):1383-1392
pubmed: 33631004